Open AccessA New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans
Author(s) -
Arome Solomon Odiba,
Olanrewaju Ayodeji Durojaye,
Ifeoma M. Ezeonu,
Anthony C. Mgbeahuruike,
Bennett C. Nwanguma
Publication year - 2022
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s360973
Subject(s) - biology , lanosterol , candida albicans , fluconazole , candida tropicalis , gene , candida glabrata , protein data bank (rcsb pdb) , genetics , in silico , computational biology , microbiology and biotechnology , biochemistry , antifungal , sterol , cholesterol
Resistance to antifungal drugs for treating Candida infections remains a major concern globally despite the range of medications available. Most of these drugs target key proteins essential to the life cycle of the organism. An enzyme essential for fungal cell membrane integrity, lanosterol 14-α demethylase (CYP51), is encoded by the ERG11 gene in Candida species. This enzyme is the target of azole-based drugs. The organism has, however, devised molecular adaptations to evade the activity of these drugs.